Halozyme Therapeutics

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Trade Halozyme Therapeutics 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About HALO

Halozyme Therapeutics, Inc. is a biopharmaceutical technology platform company. It engages in developing, manufacturing, and commercializing drug-device combination products using advanced auto-injector technology that are designed to provide commercial or functional advantages such as improved convenience and tolerability, and enhanced patient comfort and adherence. 

CEO
Helen I. Torley
CEOHelen I. Torley
Employees
423
Employees423
Headquarters
San Diego, California
HeadquartersSan Diego, California
Founded
1998
Founded1998
Employees
423
Employees423

HALO Key Statistics

Market cap
11.48B
Market cap11.48B
Price-Earnings ratio
25.88
Price-Earnings ratio25.88
Dividend yield
—
Dividend yield—
Average volume
2.60M
Average volume2.60M
High today
$102.08
High today$102.08
Low today
$100.27
Low today$100.27
Open price
$101.58
Open price$101.58
Volume
1.43M
Volume1.43M
52 Week high
$134.00
52 Week high$134.00
52 Week low
$61.23
52 Week low$61.23

Stock Snapshot

As of today, Halozyme Therapeutics(HALO) shares are valued at $100.54. The company's market cap stands at 11.48B, with a P/E ratio of 25.88.

On 2026-11-13, Halozyme Therapeutics(HALO) stock traded between a low of $100.27 and a high of $102.08. Shares are currently priced at $100.54, which is +0.3% above the low and -1.5% below the high.

Halozyme Therapeutics(HALO) shares are trading with a volume of 1.43M, against a daily average of 2.6M.

In the last year, Halozyme Therapeutics(HALO) shares hit a 52-week high of $134.00 and a 52-week low of $61.23.

In the last year, Halozyme Therapeutics(HALO) shares hit a 52-week high of $134.00 and a 52-week low of $61.23.

HALO News

Simply Wall St 5h
Why Is Halozyme Therapeutics Drawing Fresh Attention Today?

Halozyme Therapeutics earnings event Halozyme Therapeutics (HALO) just put fresh numbers on the table, with third quarter 2026 results and raised full year gui...

Why Is Halozyme Therapeutics Drawing Fresh Attention Today?
Zacks 3d
Halozyme Therapeutics is an Incredible Growth Stock: 3 Reasons Why

Growth investors focus on stocks that are seeing above-average financial growth, as this feature helps these securities garner the market's attention and delive...

Halozyme Therapeutics is an Incredible Growth Stock: 3 Reasons Why
Seeking Alpha 7d
Halozyme dips as Leerink downgrades on “marginal” Q3 upside

Halozyme Therapeutics (HALO) shed more than 13% on Friday as Leerink Partners downgraded the developer of Enhanze drug delivery technology, noting that its rece...

Halozyme dips as Leerink downgrades on “marginal” Q3 upside

Analyst ratings

55%

of 11 ratings
Buy
54.5%
Hold
36.4%
Sell
9.1%

More HALO News

Simply Wall St 7d
Earnings Beat Could Change The Case For Halozyme Stock

Halozyme Therapeutics reported third quarter 2026 revenue of US$492.97 million and net income of US$247.05 million, with both revenue and earnings per share abo...

Earnings Beat Could Change The Case For Halozyme Stock

People also own

Based on the portfolios of people who own HALO. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.